Skip to main content
H

HERON NEUTRON MEDICAL CORP. — Investor Relations & Filings

Ticker · 7799 LEI · 984500FDCFAACXT77020 TW Manufacturing
Open in API
Filings indexed 42 across all filing types
Latest filing 2026-04-24 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 7799

About HERON NEUTRON MEDICAL CORP.

https://www.heron-neutron.com/

Heron Neutron Medical Corp. specializes in the development and deployment of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) systems. The company provides end-to-end integrated solutions for oncology, encompassing the design and manufacture of high-precision accelerator systems, neutron beam moderators, treatment planning software, and treatment control systems. Its core technology facilitates targeted radiation therapy designed to maximize efficacy while minimizing treatment duration and side effects for cancer patients. Heron Neutron Medical is a pioneer in the commercialization of large-scale medical equipment, offering a comprehensive technology platform that includes both hardware and specialized boron-containing drugs. Through collaborations with clinical and academic institutions, the company focuses on establishing advanced BNCT centers to expand the availability of precision care and innovative cancer treatment options.

Recent filings

Filing Released Lang Actions
114年第4季財務報告書 — 202501_7799_AIB.pdf
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the three-month period ended March 31, 2025, including balance sheets, statements of comprehensive income, statements of changes in equity, statements of cash flows, and detailed notes to the financial statements. It includes an independent auditors' review report. This fits the definition of an Interim/Quarterly Report (IR) as it contains substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2025
2026-04-24 English
114年第4季財務報告書 — 202501_7799_AI2.pdf
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the first quarter of 114 and 113 (fiscal years), including a balance sheet, income statement, statement of changes in equity, cash flow statement, and detailed notes to the financial statements. It includes an independent auditor's review report. This fits the definition of an Interim/Quarterly Report (IR). Q1 2025
2026-04-24 Chinese
115年第1季海外子公司投資
Interim / Quarterly Report Classification · 1% confidence The document is a structured table from the Taiwan Stock Exchange's Market Observation Post System (MOPS) detailing overseas subsidiary investments for the first quarter of the 115th year (Republic of China calendar). It contains specific financial data regarding investment balances and profit/loss recognition. As it provides substantive financial data for a specific interim period (Q1) rather than just an announcement of a report, it falls under the category of Interim/Quarterly Report. Q1 2026
2026-04-23 Chinese
115年第1季大陸投資
Regulatory Filings Classification · 1% confidence The document is a standalone regulatory disclosure of a Taiwanese listed company’s direct investment in Mainland China, showing investment amounts, shareholding ratios, and regulatory approval limits under the Ministry of Economic Affairs Investment Commission. It is neither a full annual or interim report nor an announcement of a report; rather it is a specific mandatory filing for foreign investment disclosures. This does not match any more specific category, so it falls under general Regulatory Filings (RNS).
2026-04-23 Chinese
115年第1季權益變動表
Interim / Quarterly Report Classification · 1% confidence The document is a 'Consolidated Statement of Changes in Equity' (合併權益變動表) for the first quarter of 2026 (民國115年第1季). It is provided by a company (禾榮科) and contains detailed financial data for the current and prior periods. Since it provides substantive financial statements for a quarterly period, it falls under the category of Interim/Quarterly Report (IR). Q1 2026
2026-04-23 English
115年第1季現金流量表
Interim / Quarterly Report Classification · 1% confidence The document is a Consolidated Statement of Cash Flows for the first quarter of the 115th year (Republic of China calendar), provided by '禾榮科公司' (Herongke Company). It contains detailed financial data for the period from January 1 to March 31. Since it provides substantive financial statements for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report (IR). Q1 2026
2026-04-23 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.